Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (4541)	12/16/2005 12:10:09 PM
From: rkrw	Read Replies (2) \| Respond to of 4974

I've looked at cgtk. In fact bought some after the merge was announced but sold after taking it in some more. Reminds me, did bvf keep their cgtk stake? Curious if they added, bailed or stood pat. pedi device I think is a decent opp given small salesforce need. But still we're probably talking 50M bucks if it does really well. I think there's a need, but my worry is the algo device is a big and bulky thing, may be intimidating to young kids. Another concern a pedi nurse raised to me is often kids need several areas anesthetized (don't always know which spot will work), so the cream is very amenable to that. algo device may not be. Eczema trial, I think it's a low probability. Caspaicin injection is interesting. Seems to work very well. But patients need to be put under for it since it gives a bad burning sensation. So far from perfect. I was also concerned about the post merge burn rate. cgtk wouldn't answer that simple question. A reverse merge in the pain space I found more interesting was maxm/epicept. Supposed to close next week. Cash position isn't nearly as strong as cgtk, but the market cap reflects that (more like 130M but they'll need to raise some cash, roughly 20M).